Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01355614 | A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients | PHASE2 | COMPLETED | 10 | — | — | Jun 1, 2011 | Mar 1, 2013 | Feb 23, 2017 | 6 | Germany, Switzerland |
| Arm | Type | Description |
|---|---|---|
| QAX576 | EXPERIMENTAL | - |
| Infliximab | OTHER | - |
| Name | Type | Description |
|---|---|---|
| QAX576 | DRUG | - |
| Infliximab | DRUG | - |
Inclusion Criteria: * At least one draining enterocutaneous perianal fistula * Diagnosis of Crohn's disease (CD) must have been established for at least 6 months * At least one ineffective fistula treatment (but no previously failed anti-TNFα (tumour necrosis factor) antibody treatment) * Patients ...